Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	ObsEva	Calithera Biosciences	Savara	Matinas BioPharma	Lantern Pharma
Symbol	NASDAQ:OBSV	NASDAQ:CALA	NASDAQ:SVRA	NYSEAMERICAN:MTNB	NASDAQ:LTRN
Price Information
Current Price	$3.08	$2.05	$1.28	$1.16	$12.29
50-Day Moving Average	$2.75	$2.16	$1.35	$1.11	$13.17
52-Week Low	$1.86	$1.78	$1.00	$0.67	$10.29
52-Week High	$5.55	$6.18	$3.58	$2.22	$24.84
MarketRank™
Overall Score	1.6	2.2	2.2	1.8	2.0
Analysis Score	3.3	3.3	3.5	3.4	3.5
Community Score	4.3	4.8	4.4	4.8	5.0
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	2.5	3.3	0.0	1.7
Earnings & Valuation Score	0.6	0.6	0.0	0.6	0.0
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$14.33	$3.67	$4.67	$3.33	$29.00
% Upside from Price Target	365.37% upside	78.86% upside	264.58% upside	187.36% upside	135.96% upside
Trade Information
Market Cap	$177.26 million	$151.93 million	$145.73 million	$249.10 million	$137.45 million
Beta	0.78	1.69	1.23	2.64	1.37
Average Volume	3,057,479	1,126,238	2,105,937	2,687,695	130,243
Sales & Book Value
Annual Revenue	$20,000.00	$22.25 million	$260,000.00	$160,000.00	N/A
Price / Sales	8,863.16	6.83	560.48	1,556.87	N/A
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$0.15 per share	$1.45 per share	$1.19 per share	$0.30 per share	$1.88 per share
Price / Book	20.53	1.41	1.08	3.87	N/A
Profitability
Net Income	$-82,970,000.00	$-90,140,000.00	$-49,620,000.00	$-22,450,000.00	$-5,910,000.00
EPS	($1.67)	($1.31)	N/A	($0.12)	($1.37)
Trailing P/E Ratio	N/A	N/A	0.00	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	N/A	N/A	N/A	N/A
Return on Equity (ROE)	-269.94%	-79.58%	-38.18%	-34.47%	-18.49%
Return on Assets (ROA)	-94.67%	-66.42%	-30.08%	-29.90%	-18.03%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.61%	N/A	0.15%	N/A	N/A
Current Ratio	3.64%	7.53%	32.56%	16.97%	30.56%
Quick Ratio	3.64%	7.53%	32.56%	16.97%	30.55%
Ownership Information
Institutional Ownership Percentage	31.71%	63.29%	66.92%	17.92%	12.05%
Insider Ownership Percentage	N/A	11.60%	4.77%	7.80%	30.30%
Miscellaneous
Employees	45	93	N/A	20	13
Shares Outstanding	57.55 million	74.11 million	113.85 million	214.74 million	11.18 million
Next Earnings Date	11/4/2021 (Estimated)	11/4/2021 (Estimated)	11/4/2021 (Estimated)	11/5/2021 (Estimated)	11/4/2021 (Estimated)
Optionable	Not Optionable	Optionable	Optionable	Not Optionable	Not Optionable

Source	Headline
	Lantern Pharma Inc money.usnews.com - September 14 at 10:28 PM
	Lantern Pharma to Participate in Two Upcoming Virtual Investor Conferences During September finance.yahoo.com - September 7 at 6:25 PM
	Lantern Pharma Expands Management Team with Appointment of Two Leading Industry Executives to Support Clinical and Manufacturing Initiatives finance.yahoo.com - September 2 at 4:53 PM
	Lantern Pharma: FDA Grants Additional Orphan Drug Designation For LP-184 - Quick Facts nasdaq.com - August 30 at 4:11 PM
	FDA Grants Lantern Pharma Additional Orphan Drug Designation for Drug Candidate LP-184 in Glioblastoma Multiforme & Malignant Gliomas finance.yahoo.com - August 30 at 9:17 AM
	Preclinical Data Of Brain Tumor Candidate Fails To Lift Lantern Pharma Stock finance.yahoo.com - August 25 at 7:39 PM
	Lantern Pharma Inc. barrons.com - August 19 at 4:24 PM
	Lantern Pharma Reports Positive Data From Preclinical Study With LP-184 In Glioblastoma markets.businessinsider.com - August 19 at 4:24 PM
	Lantern Pharma Announces Positive Preclinical Data in Glioblastoma (GBM) with Drug Candidate LP-184 and Expands GBM Research Collaboration finance.yahoo.com - August 19 at 11:24 AM
	Lantern Pharma Announces Abstract on Effectiveness of LP-184 in Pancreatic Cancers Accepted for Presentation at the AACR Virtual Special Conference: Pancreatic Cancer finance.yahoo.com - August 16 at 9:33 AM
	Lantern Pharma Gets FDA Orphan Designation for LP-184 in Pancreatic Cancer >LTRN marketwatch.com - August 11 at 12:57 PM
	Lantern Pharma's LP-184 Gets Orphan Drug Designation In Treatment Of Pancreatic Cancer nasdaq.com - August 11 at 12:57 PM
	FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-184 in the Treatment of Pancreatic Cancer finance.yahoo.com - August 11 at 12:57 PM
	How Many Lantern Pharma Inc. (NASDAQ:LTRN) Shares Do Institutions Own? finance.yahoo.com - August 9 at 1:11 PM
	LTRN: 2Q:21 Results finance.yahoo.com - August 5 at 12:27 PM
	Lantern Pharma Reports Second Quarter 2021 Financial Results and Operational Highlights finance.yahoo.com - July 29 at 7:23 PM
	Lantern Pharma Reacquires Rights To Commercialization Of Irofulven cmlviz.com - July 27 at 12:13 PM
	Lantern Pharma Reacquires Rights To Phase 2 Clinical Trial In Metastatic Prostate Cancer nasdaq.com - July 27 at 12:13 PM
	Lantern Pharma Reacquires Rights to Phase 2 Clinical Trial in Metastatic Prostate Cancer and Global Development & Commercialization of Irofulven (LP-100) from Allarity Therapeutics A/S finance.yahoo.com - July 27 at 12:13 PM
	Allarity Therapeutics and Lantern Pharma Enter into Agreement for Future Clinical Development of Irofulven wallstreet-online.de - July 26 at 3:26 AM
	Lantern Pharma to Host Second Quarter 2021 Operating and Financial Results Conference Call on Thursday, July 29, 2021 at 4:30 p.m. ET finance.yahoo.com - July 22 at 6:09 PM
	“The Buzz” Show: Lantern Pharma (NASDAQ: LTRN) Positive Cancer Collaboration Data financialbuzz.com - July 20 at 6:05 PM
	The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street msn.com - July 20 at 1:05 PM
	Lantern Pharma Shares Moves Higher On Encouraging Data From Pancreatic Cancer Candidate In Animal Models finance.yahoo.com - July 20 at 1:05 PM
	Lantern Pharma Announces Significant Positive Preclinical Data in Pancreatic Cancer With Drug Candidate LP-184 finance.yahoo.com - July 20 at 8:04 AM

Date	Company	Brokerage	Action
9/15/2021	ObsEva	HC Wainwright	Reiterated Rating
9/14/2021	Matinas BioPharma	HC Wainwright	Reiterated Rating
8/9/2021	ObsEva	HC Wainwright	Reiterated Rating
8/9/2021	Calithera Biosciences	HC Wainwright	Reiterated Rating
7/30/2021	Lantern Pharma	Colliers Securities	Reiterated Rating
7/28/2021	ObsEva	Wedbush	Reiterated Rating
7/21/2021	Lantern Pharma	Colliers Securities	Reiterated Rating
7/2/2021	ObsEva	Wedbush	Reiterated Rating
5/14/2021	Savara	HC Wainwright	Reiterated Rating
5/11/2021	Matinas BioPharma	Piper Sandler	Downgrade
5/10/2021	Calithera Biosciences	HC Wainwright	Reiterated Rating
3/30/2021	Matinas BioPharma	HC Wainwright	Reiterated Rating
3/16/2021	Savara	Piper Sandler	Initiated Coverage
3/15/2021	Savara	Oppenheimer	Initiated Coverage
2/15/2021	Matinas BioPharma	Aegis	Reiterated Rating
1/29/2021	Matinas BioPharma	Maxim Group	Reiterated Rating
1/12/2021	ObsEva	Wedbush	Reiterated Rating
1/12/2021	ObsEva	SVB Leerink	Boost Price Target
1/5/2021	Calithera Biosciences	Smith Barney Citigroup	Lower Price Target
1/5/2021	Calithera Biosciences	HC Wainwright	Lower Price Target
1/5/2021	Calithera Biosciences	SVB Leerink	Downgrade
1/4/2021	ObsEva	HC Wainwright	Lower Price Target
1/4/2021	Matinas BioPharma	Piper Sandler	Boost Price Target
12/15/2020	Savara	HC Wainwright	Lower Price Target
11/23/2020	Savara	Evercore ISI	Initiated Coverage
11/9/2020	ObsEva	JPMorgan Chase & Co.	Downgrade
11/6/2020	Matinas BioPharma	Maxim Group	Initiated Coverage
10/5/2020	ObsEva	HC Wainwright	Lower Price Target
8/18/2020	Lantern Pharma	ThinkEquity	Reiterated Rating
8/18/2020	Lantern Pharma	Colliers Securities	Reiterated Rating
8/14/2020	ObsEva	Wedbush	Reiterated Rating
8/13/2020	Matinas BioPharma	Aegis	Boost Price Target
8/11/2020	Calithera Biosciences	SVB Leerink	Lower Price Target
8/11/2020	Matinas BioPharma	HC Wainwright	Reiterated Rating
8/10/2020	Lantern Pharma	ThinkEquity	Initiated Coverage
7/28/2020	Lantern Pharma	Colliers Securities	Initiated Coverage
7/7/2020	ObsEva	SVB Leerink	Lower Price Target
7/7/2020	ObsEva	JPMorgan Chase & Co.	Downgrade
7/6/2020	ObsEva	BMO Capital Markets	Downgrade
7/1/2020	ObsEva	HC Wainwright	Reiterated Rating
7/1/2020	ObsEva	Wedbush	Reiterated Rating
6/5/2020	ObsEva	HC Wainwright	Reiterated Rating
6/2/2020	Calithera Biosciences	William Blair	Reiterated Rating
6/2/2020	Matinas BioPharma	Aegis	Reiterated Rating
5/23/2020	Matinas BioPharma	Maxim Group	Initiated Coverage
5/13/2020	Matinas BioPharma	Maxim Group	Reiterated Rating
5/11/2020	Calithera Biosciences	Citigroup	Boost Price Target
5/8/2020	Calithera Biosciences	HC Wainwright	Reiterated Rating
5/5/2020	ObsEva	Wedbush	Reiterated Rating
4/1/2020	Matinas BioPharma	Maxim Group	Initiated Coverage
3/27/2020	Calithera Biosciences	Citigroup	Lower Price Target
3/27/2020	Calithera Biosciences	Jefferies Financial Group	Initiated Coverage
3/23/2020	ObsEva	Wedbush	Reiterated Rating
3/23/2020	ObsEva	HC Wainwright	Lower Price Target
3/17/2020	Savara	HC Wainwright	Reiterated Rating
3/11/2020	Calithera Biosciences	SVB Leerink	Reiterated Rating
3/6/2020	Matinas BioPharma	Maxim Group	Reiterated Rating
3/5/2020	ObsEva	Wedbush	Boost Price Target
1/26/2020	Matinas BioPharma	Piper Sandler	Initiated Coverage
1/23/2020	Matinas BioPharma	SunTrust Banks	Initiated Coverage
1/21/2020	ObsEva	Wedbush	Reiterated Rating
1/21/2020	ObsEva	HC Wainwright	Reiterated Rating
1/9/2020	Matinas BioPharma	Aegis	Initiated Coverage
12/20/2019	Savara	HC Wainwright	Reiterated Rating
12/20/2019	Matinas BioPharma	HC Wainwright	Reiterated Rating
12/19/2019	ObsEva	HC Wainwright	Reiterated Rating
12/10/2019	ObsEva	Royal Bank of Canada	Boost Price Target
12/2/2019	ObsEva	HC Wainwright	Reiterated Rating
11/27/2019	Calithera Biosciences	HC Wainwright	Initiated Coverage
11/19/2019	Calithera Biosciences	HC Wainwright	Initiated Coverage
10/3/2019	Savara	LADENBURG THALM/SH SH	Reiterated Rating
9/26/2019	Matinas BioPharma	Maxim Group	Reiterated Rating
8/14/2019	Matinas BioPharma	HC Wainwright	Reiterated Rating
8/12/2019	Savara	Evercore ISI	Set Price Target
8/9/2019	Calithera Biosciences	Citigroup	Set Price Target
6/26/2019	Matinas BioPharma	HC Wainwright	Reiterated Rating
6/26/2019	Matinas BioPharma	HC Wainwright	Initiated Coverage
6/21/2019	Calithera Biosciences	William Blair	Reiterated Rating
6/13/2019	Savara	Canaccord Genuity	Lower Price Target
6/13/2019	Savara	HC Wainwright	Lower Price Target
6/13/2019	Savara	LADENBURG THALM/SH SH	Downgrade
6/13/2019	Savara	JMP Securities	Downgrade
5/30/2019	Calithera Biosciences	Citigroup	Reiterated Rating
5/17/2019	Matinas BioPharma	BTIG Research	Initiated Coverage
5/16/2019	Matinas BioPharma	Maxim Group	Reiterated Rating
5/14/2019	Savara	Roth Capital	Set Price Target
5/10/2019	Savara	LADENBURG THALM/SH SH	Reiterated Rating
4/1/2019	Savara	LADENBURG THALM/SH SH	Reiterated Rating
3/25/2019	Savara	Canaccord Genuity	Set Price Target
2/11/2019	Matinas BioPharma	Roth Capital	Reiterated Rating
12/20/2018	Savara	HC Wainwright	Reiterated Rating
11/8/2018	Savara	HC Wainwright	Reiterated Rating

(Data available from 9/16/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources